Immunoglobulin E specific for Phoenix dactylifera pollen allergens (sIgE)

Immunoglobulin E (IgE) antibodies specific for Phoenix dactylifera (date palm) pollen allergens are the primary mediators of Type I hypersensitivity reactions to date palm pollen, a major aeroallergen in arid and subtropical regions (PMID: 15120013). These antibodies are produced following sensitization to specific pollen proteins, such as the profilin Pho d 2 or the polcalcin Pho d 4 (WHO/IUIS Allergen Nomenclature). Once formed, these specific IgE (sIgE) molecules bind to high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to Phoenix dactylifera pollen, the allergens cross-link the bound IgE, triggering the release of inflammatory mediators like histamine and leukotrienes. This inflammatory cascade leads to clinical symptoms of allergic rhinitis, conjunctivitis, and bronchial asthma (PMID: 10852370). While systemic anti-IgE therapies like Omalizumab target the entire IgE pool by binding the Cε3 domain to prevent receptor interaction, allergen-specific immunotherapy (AIT) specifically targets the immune response to these allergens to induce long-term tolerance (FDA Label: Xolair). Monitoring the levels of these specific antibodies is essential for clinical diagnosis and for evaluating the progress of desensitization treatments.

Other names

Phoenix dactylifera-specific IgEDate palm pollen-specific IgEsIgE to Phoenix dactyliferaAnti-date palm IgEDate palm-specific Immunoglobulin E

Omalizumab binds to the Cε3 domain of free IgE, preventing its interaction with the high-affinity FcεRI receptor on mast cells and basophils, thereby inhibiting the allergic cascade. Allergen-specific immunotherapy (AIT) works by inducing the production of IgG4 blocking antibodies and promoting T-cell tolerance, which reduces the activation of IgE-mediated pathways.